Annual rank74
Germany · Healthcare
M1 Kliniken
M1 Med Beauty treatments are offered at more than 35 centres; its Berlin facility has six operating theatres.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Treatments, medical standards and a repeatable clinic model
M1 Kliniken is a medical-aesthetics group built around the M1 Med Beauty clinic format. Doctors deliver a deliberately focused set of injectable and surgical procedures, supported by central purchasing, common protocols and the M1 Akademie training system. Outpatient centres handle recurring consultations and treatments, while the Berlin Schlossklinik concentrates plastic surgery. Following the disposal of HAEMATO Pharm, the group describes itself as a vertically integrated pure-play provider of medical aesthetics.
Treatments and access
A focused menu delivered through specialist centres
M1 Med Beauty centres concentrate on hyaluronic-acid fillers, muscle-relaxant injections and selected plastic surgery. Each treatment begins with a doctor consultation; the narrow menu is intended to build repetition and specialist routine rather than recreate a general clinic at every address.
- Explore all treatments Injectables, facial contouring and selected cosmetic surgery
- M1 Med Beauty The brand's treatment focus and specialist-centre format
- Find a specialist centre German locations and the consultation pathway
- How the group is structured Clinics, surgery, products and international presence
Surgery and medical standards
Hospital-level procedures are concentrated in Berlin
The M1 Schlossklinik in Berlin-Köpenick handles procedures including breast surgery, liposuction, eyelid lifts and body contouring. Its operating theatres, beds and specialist teams separate surgery from the lighter outpatient network. Group rules reserve injectable treatments for doctors and surgery for plastic-and-aesthetic specialists.
- Inside the Schlossklinik Surgical procedures, specialists and the Berlin facility
- Clinic management and hygiene Medical leadership, equipment and quality assurance
- Medical standards in the annual report Specialisation, audits, hygiene and product selection
- Expanding surgical capacity How surgical hubs complement nearby outpatient centres
Operating model
Training and purchasing make the format repeatable
The M1 Akademie gives physicians, specialists and dentists practical training in procedures, product use and complication management. Common protocols, internal audits, central procurement and high utilisation support consistent delivery when the brand enters another city or country. The same premises have also been used to add services such as laser treatment.
- M1 Akademie Practical techniques, products and complication management
- The specialisation model Focused treatments, central purchasing and doctor training
- M1 Laser rollout Adding diode-laser services within existing centres
- Corporate development How the Berlin format became an international network
Footprint and strategic focus
A ten-country network is now a pure-play business
M1 reported 59 clinics in ten countries in June 2026, with Germany at the centre and operations extending across Europe and Australia. The sale of HAEMATO Pharm to the PHOENIX group was completed in January 2026, removing the large pharmaceutical-trading activity and sharpening the group's stated focus on medical aesthetics.
- Current network and strategy The 59-clinic, ten-country footprint reported with Q1 2026 results
- German clinic map Addresses and patient access across the home market
- The pure-play transition Exact completion notice for the HAEMATO Pharm disposal
- M1 Select The group's medical-cosmetics brand and distribution model
Official profile sources: Unternehmensprofil - M1 Kliniken AG · M1 Kliniken AG publishes annual report for 2025 · Company: About M1 Kliniken AG - M1 Kliniken AG
Current 2026 update
What is changing at M1 Kliniken in 2026?
M1 entered 2026 as a mixed beauty-and-pharma group and emerged from January with Beauty as its stated strategic focus. The assets are familiar; the change is that clinics, surgery and physician training now carry the strategy without HAEMATO Pharm's wholesale operation.
The change in one sentence
A portfolio exit has turned the clinic format into the whole strategic story.
The completed HAEMATO Pharm disposal removes wholesale pharma; M1 must now scale a 59-clinic medical model while preserving the standards it attributes to specialisation and training.
Four lenses on 2026
The same four-quadrant format used in the Company profile.
01 · Pure-play reset
The pharmaceutical wholesaler left through a two-level ownership chain
M1 held no direct stake in HAEMATO Pharm. Its exposure was indirect: M1 owns 85% of HAEMATO AG, which owned 100% of HAEMATO Pharm and sold that company to PHOENIX. M1 announced on 2 February that all closing conditions, including antitrust approvals, had been fulfilled and that the transaction was legally complete effective at the end of 31 January. HAEMATO Pharm was then deconsolidated from both HAEMATO AG and M1 Kliniken. The Q1 release describes this as completion of the group's strategic refocusing on Beauty; it does not disclose the sale price. The accounting transition makes headline comparisons unusually poor: Q1 group revenue still includes one month of Trading, while the result contains a non-cash deconsolidation gain. The durable change is simpler than those accounts: a large pharmaceutical-wholesale activity has left, and M1 states that it has aligned the portfolio around Beauty, although consolidated Q1 figures still contain one month of Trading.
- Current signalHAEMATO AG 85%-owned · HAEMATO Pharm 100%-owned by HAEMATO AG · legal completion 31 January
- Why it mattersThe disposal changes what M1 operates and makes the clinic business, rather than pharmaceutical distribution, the principal test of execution.
- HAEMATO ownership and completion M1 Kliniken · 2 February 2026
- Q1 pure-play update M1 Kliniken · 3 June 2026
02 · Clinical pathway
A narrow treatment menu now defines the group
The operating pieces predate the disposal. M1's outpatient centres concentrate on hyaluronic-acid fillers, muscle-relaxant injections and selected treatments, beginning with a physician consultation. Complex plastic and aesthetic surgery is concentrated at Berlin's Schlossklinik, which M1 describes as having four operating theatres and 35 beds. The M1 Akademie trains physicians, specialists and dentists in procedures, products and complication management. M1 presents uniform training as a way to support consistent quality across locations; that is an operating mechanism, not proof of identical outcomes. What changed in 2026 is the weight of this system inside the group. With HAEMATO Pharm deconsolidated, the 59 clinics in ten countries, the Berlin surgical hub and the training programme no longer sit beside a much larger wholesale business. M1 plans to expand the outpatient clinic network in Germany and abroad, supported by centralised surgical capacity in Berlin and standardised training through the Akademie.
- Current signal59 clinics · ten countries · four operating theatres · one in-house training system
- Why it mattersM1's growth case now rests on repeating a specialised treatment pathway while keeping clinical roles and standards coherent.
- Q1 pure-play update M1 Kliniken · 3 June 2026
- Treatment pathway M1 Med Beauty · Current official page
- Berlin surgical hub M1 Med Beauty · Current official page
- Physician training model M1 Kliniken · Current official page
03 · Replication test
The 2029 target has a model, but no disclosed opening calendar
M1 targets Beauty revenue of €200-300 million by 2029 at a sustainable EBIT margin of at least 20%. Its stated route is further clinic expansion in Germany and abroad, but the June release names no acquisition, new country, clinic-opening timetable or annual guidance. Q1 Beauty revenue rose 5.7% to €27.1 million and EBIT to €9.2 million, producing a 33.9% margin versus 26.0% a year earlier. Those issuer-reported figures describe the Beauty segment after the portfolio reset; they do not guarantee that one quarter's profitability will persist as the network grows. The strategic question is therefore operational: can M1 add medical capacity and locations quickly enough while preserving M1's stated rule that treatments are performed by qualified physicians, the specialist-surgery boundary and the training system? Until later disclosures name openings and their contribution, the 2029 range remains an issuer target without a documented rollout plan.
- Current signal€200-300m Beauty target by 2029 · ≥20% margin target · no named opening calendar
- Why it mattersM1 presents the outpatient format as repeatable, but expansion speed and medical consistency must still be demonstrated at the next scale.
- Q1 pure-play update M1 Kliniken · 3 June 2026
- Treatment pathway M1 Med Beauty · Current official page
- Physician training model M1 Kliniken · Current official page
04 · What to watch
Three questions for the next disclosures
The next operating disclosures should make the pure-play structure and expansion path more concrete.
- Clean comparabilityHow does the Beauty segment read once the one-month Trading and deconsolidation effects leave the comparison?
- Named openingsWhich clinics, countries or acquisitions are actually added toward the 2029 revenue range?
- Medical consistencyWhat training, audit and patient-quality evidence accompanies faster clinic and surgical-capacity growth?
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 74 | +28% | +413% | +124% |